Among 29 melanoma patients and 19 NSCLC patients treated with nivolumab or pembrolizumab, the serum concentration of IL‐8 showed a significant reduction in patients with the best response and a dramatic elevation in patients with true progression and nonresponders compared to the baseline level. This evidence concerns the gene CXCL8 and melanoma.